Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Future Events
7th May 2024
8:30 - 9:30 AM
SHINGRIX Encore TV is back with more reruns for you!
Keep up with us every Wednesday as we deep dive into herpes zoster. Here's a list of suitable timings and dates for you to pick and choose.
SHINGRIX Encore TV is back with more reruns for you!
Keep up with us every Wednesday as we deep dive into herpes zoster. Here's a list of suitable timings and
dates for you to pick and choose.
Optimising Patient Outcomes: Integrating Shingrix into HIV Care Plans
by Assoc. Prof. Dr. Raja Iskandar Raja Azwa, Associate Professor in Infectious Diseases
Connecting The Dots: Investigating The Correlation Between Shingles and Renal Diseases
by Dr. Rosnawati Yahya, Resident Nephrologist
Herpes Zoster Vaccination in Adults Aged 50+ and Co-morbid Patients: A Different Perspective
by Dr. Peter Ch'ng, Consultant Dermatologist
Shingrix Safety Information:
Contraindication:
Hypersensitivity to the active substances or to any component of the vaccine.
Very common adverse events include headache, gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain), myalgia, injection site reactions (such as pain, redness, swelling), fatigue, chills, fever.
Before prescribing, please refer to the full prescribing information available here.
Reference:
- Shingrix Prescribing Information
Trade marks are owned by or licensed to the GSK group of companies.
PM-MY-SGX-WCNT-250003 08/25
